Healthtech

Austrian Biotech Efferon Secures €2.5M Seed Funding to Expand Sepsis Treatment Manufacturing Across Europe

by

Efferon, a biotech company developing hemoadsorption devices for treating sepsis and septic shock, has secured €2.5 million in seed funding led by private investors from the DACH region. The company will use funds to build a new EU production facility and expand manufacturing capacity. Efferon’s products include Efferon LPS for general use and Efferon NEO for pediatric patients, with the latter recently receiving CE MDR certification. The technology has been used in over 25,000 treatments across 40+ countries.

Swedish Digital Therapeutics Company Paindrainer Secures €550,000 in Growth Funding

by

Paindrainer, a Swedish digital therapeutics company based in Lund, has raised €550,000 from existing shareholder Almi Invest, Tramontane Invest, and other existing and new shareholders. The company develops AI-powered digital platforms for chronic pain management, including its flagship PD Care System and the upcoming Relivra product powered by proprietary Artificial Neural Networks.

UK Healthtech Startup NEX Health Intelligence Raises €1 Million to Expand AI-Powered Infection Prevention Platform

by

NEX Health Intelligence, a healthtech startup, has raised €1 million in pre-seed funding to develop an AI-powered infection intelligence platform designed to help hospitals detect, predict and prevent healthcare-associated infections. The platform has already supported infection safety across more than 40,000 patient admissions internationally and is currently working with NHS organisations in the UK and hospitals in Southeast Asia.

Polish Stem Cell Company Bioceltix Advances Canine Osteoarthritis Treatment Through EMA Regulatory Process

by

Bioceltix, a Wrocław-based stem cell company, has submitted responses to regulatory questions from the European Medicines Agency (EMA) regarding its lead therapeutic candidate BCX-CM-J for canine osteoarthritis. This represents a key milestone in the drug registration process ahead of market approval.

Spanish genomics startup BioGenómika wins EmprendeXXI Awards for innovation potential in Extremadura

by

BioGenómika, certified as an emerging company by Enisa, has won the EmprendeXXI Awards recognizing it as the innovative company with the greatest potential and impact in Extremadura. The awards are promoted by Enisa through the Ministry of Industry and Tourism, and CaixaBank through DayOne, its division specialized in technology companies.

Farm Innovations and DOGid Partner to Strengthen Animal Identification and Pet Reunification in Europe

by

Farm Innovations S.A., a vet-tech company listed on NewConnect specializing in animal identification and health monitoring, has entered into a partnership with DOGid, which has operated a verified and regularly updated database of domestic animals for over 20 years. The partnership aims to create a quality animal identification system based on high-reliability data to increase the chances of lost pets being quickly reunited with their owners.

Danish Biotech Startup Alcolase Secures €1.5M to Develop Enzyme Treatment for Genetic Alcohol Intolerance

by

Danish biotech startup Alcolase raised €1.5 million to develop an enzyme-based technology that breaks down alcohol in the stomach before absorption, targeting the 540 million people in East Asia with ALDH2 deficiency (genetic alcohol intolerance). The company plans to launch in Singapore and South Korea, with a UK subsidiary supporting therapeutic drug delivery development.

Italian Biotech Firm Sends Bone Substitute to International Space Station in Landmark Research Mission

by

GreenBone Ortho, an Italian biotech company specializing in bone regeneration, sent its innovative b.Bone bone substitute to the International Space Station aboard SpaceX CRS-34 on May 15-16, 2026. The experiment aims to test how human bone cells adhere, proliferate, and differentiate on the scaffold material in microgravity conditions. The research is a collaboration with San Martino Hospital and University of Genova, with technical partners Kayser Space and Comat providing the specialized equipment. Initial results are expected by end of 2026.